-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

704.O1.6 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Lymphoma

Symposia: Cellular Immunotherapies: Early Phase and Investigational Therapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Hodgkin lymphoma, Biological therapies, Lymphomas, non-Hodgkin lymphoma, Translational Research, Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, T Cell lymphoma, Diseases, Gene Therapy, aggressive lymphoma, Therapies, Immunotherapy, Lymphoid Malignancies, Adverse Events, Natural Killer (NK) Cell Therapies
Saturday, December 10, 2022: 12:00 PM-1:30 PM
La Nouvelle Orleans Ballroom AB (Ernest N. Morial Convention Center)
Moderators:
Vanessa A Fabrizio, MD, University Of Colorado and Matthew J Frank, MD, PhD, Stanford University
Disclosures:
Fabrizio: Adaptimmune: Consultancy.
CD19 and CD30 CAR studies focused on DLBCL, PCNSL and HL.
12:00 PM

Jae H Park, MD1, M. Lia Palomba, MD2, Isabelle Riviere, PhD3, Devanjan S. Sikder3*, Brigitte Senechal, PhD3*, Xiuyan Wang, PhD3*, Vladimir P. Bermudez3*, Elizabeth R. Cathcart2*, Kelly Liotta1*, Jannakie Joseph1*, Jia Li4*, Yunqi Zhao4*, Rachael Liu, PhD4*, Sharon Chen4*, Leopold Sellner4* and Michel Sadelain, MD, PhD5

1Cellular Therapeutics Service, Memorial Sloan Kettering Cancer Center, New York, NY
2Department of Medicine, Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
3Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY
4Takeda Development Center Americas, Inc., Lexington, MA
5Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY

12:15 PM

Ana Carolina Carolina Caballero Gonzalez, MD1,2*, Laura Escribà-García, PhD3*, Rosanna Montserrat3*, Eva Escudero-López3*, Paula Pujol-Fernández3*, Cristina Ujaldón-Miró3*, Irene García-Cadenas, MD3*, Albert Esquirol, MD3*, Rodrigo Martino, MD3*, Jorge Sierra, MD, PhD4, Carmen Alvarez-Fernández, PhD3* and Javier Briones, MD, PhD5,6*

1Josep Carreras Leukaemia Research Institute, Barcelona, Spain
2Hematology Department, Hospital de la Santa Creu i Sant Pau, BARCELONA, Spain
3Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
4Hematology Department, Hospital de la Santa Creu i Sant Pau, Sant Pau Biomedical Research (IIB) and Jose Carreras Leukemia Research Institutes, Autonomous University of Barcelona, Barcelona, Spain
5Josep Carreras Leukemia Research Institute, Barcelona, Spain
6Hematology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain

12:30 PM

Ulrike Gerdemann, MD1,2, James Kaminski1,3*, Alexandre Albanese1*, Paula Keskula1,2*, Lorenzo Cagnin, PhD1,2*, Kayla Betz, BS, MPH1,2*, Jillian Zavistaski1*, Ryan A Fleming1*, Caroline Falvey4*, Riemke Bouvier4*, Julia Jones4*, Soumya Poddar, PhD5*, Mike Mattie, PhD5*, Ugonma Chukwueke4*, Alexandra Torres4*, Caron A. Jacobson, MD4, Lakshmi Nayak, MD4 and Leslie S. Kean, MD, PhD1,2

1Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston
2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
3Broad Institute of MIT and Harvard, Cambridge
4Dana-Farber Cancer Institute, Boston, MA
5Kite, a Gilead Company, Santa Monica, CA

12:45 PM

Roch Houot1*, Emmanuel Bachy, MD, PhD2*, Guillaume Cartron, MD, PhD3*, François-Xavier Gros4*, Franck Morschhauser, MD, PhD5*, Lucie Oberic, MD6*, Thomas Gastinne, MD7*, Pierre Feugier, MD8*, Remy Dulery9*, Catherine Thieblemont, MD, PhD10, Magalie Joris, MD11*, Francisco Llamas-Gutierrez12*, Emmanuel Itti, MD, PhD13*, Cedric Menard14*, Yassine Al-Tabaa15*, Clement Bailly16*, Marie-Helene Delfau17*, Camille Laurent, MD, PhD18* and Francois Lemonnier19*

1CHU de Rennes, Université de Rennes, INSERM U1236, EFS, Rennes, France
2Department of Hematology, Lyon-Sud Hospital, Pierre-Benite, France
3Département d'Hématologie clinique, CHU de Montpellier, Montpellier, France
4Hopital Du Haut-lévèQue, Pessac, FRA
5Hematology Department, Lille University Hospital, Lille, France
6Department of Hematology, Institut Universitaire Cancerologie Toulouse-Oncopole, Toulouse, France
7Hematology Department, Nantes University Hospital, Nantes, France
8Department of Hematology, Henri Poincaré University, CHU NANCY BRABOIS, Vandoeuvre Les Nancy, France
9Saint-Antoine Research Center, Inserm UMR938, Sorbonne Université, Paris, France
10Hôpital Saint-Louis, Paris, France
11Service d’Hématologie Clinique et Thérapie cellulaire, Centre Hospitalier Universitaire d’Amiens, Amiens, France
12Hemopathology lab, University hospital of Rennes, Rennes, France
13Nuclear Medicine, Henri Mondor Hospital, Créteil, France
14SITI laboratory, University Hospital Pontchaillou, Rennes, France
15Scintidoc Nuclear Medicine Center, Montpellier, France
16Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, Nantes, France
17Department of Immunology, University Hospital, Creteil, France
18Institut universitaire du cancer Toulouse-Oncopole CHU Toulouse, Toulouse, France
19Unité Hémopathie Lymphoïde, Hôpital Henri Mondor & Université Paris Est Créteil, Créteil, France

1:00 PM

David H. Quach, PhD, Carlos A. Ramos, MD, Premal D. Lulla, MBBS, Sandhya Sharma, BS*, Haran R. Ganesh, BS*, Nazila Nouraee, PhD*, Yolanda D. Briones, MS*, Yezan F. Hadidi, BS*, Luis Becerra-Dominguez, BS*, Sachin G. Thakkar, PhD*, Birju Mehta, MS*, Silvana Perconti, MS*, Emily M. Hsieh, MD*, Huimin Zhang, BS*, Bambi J. Grilley, RPh*, Malcolm K. Brenner, MD, PhD*, Helen E. Heslop, MD, DSc (Hon), Rayne H. Rouce, MD, Natalia Lapteva, PhD* and Cliona M. Rooney, PhD*

Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX

1:15 PM

Yago Nieto, MD1, Pinaki P Banerjee, PhD1*, Indreshpal Kaur, PhD1*, Lori Griffin1*, Christina Ganesh1*, Lucila Kerbauy, MD1*, Rafet Basar, MD1*, Mecit Kaplan, MS1*, Sanjida Islam1*, Daniel Esqueda1*, Roland Bassett, MS2*, Melissa Timmons, PA-C1*, Jeremy L. Ramdial, MD1, Samer A Srour, MD, MS1, Neeraj Saini, MD1, Chitra Hosing, MD1, Sairah Ahmed, MD3, Swaminathan Padmanabhan Iyer, MD3*, Karenza Alexis, MD4*, Michael Emig, MD5*, Andreas Harstrick, MD5*, Elizabeth J Shpall, MD1 and Katy Rezvani, MD1

1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
4Affimed, New York, NY
5Affimed, Heidelberg, Germany

*signifies non-member of ASH